Table 1:

Trends of HSCT worldwide and in the AFRICAN/EMRO region in 2006 and 2013

	African/EMRO region					Worldwide
	2006	2013			Δ	2006			2013	Δ
					2006–2013					2006–2013
Allogeneic HSCT
	total	related	unrelated	total		total	related	unrelated	total
Leukemia’s	492	670	50	720	46%	14392	11424	12912	24336	69%
AML	186	336	26	362	95%	6611	5592	6334	11926	80%
ALL	132	226	16	242	83%	3488	2926	2753	5679	63%
CML	139	48	0	48	-65%	1334	554	496	1050	-21%
MDS/MPS	33	52	6	58	76%	2268	1957	2745	4702	107%
CLL	2	8	2	10	400%	556	298	476	774	39%
Other leukemia	0	0	0	0	0	135	97	108	205	52%
Lymphoproliferative disorders	28	53	7	60	114%	3219	2111	2471	4582	42%
Plasma cell disorders	2	17	0	17	750%	773	450	445	895	16%
lymphomas	26	36	17	43	65%	2446	1639	2006	3645	49%
Other lymphoma/Type unknown	0	0	0	0	0	0	22	20	42	0
Solid tumors	1	0	0	0	-100%	150	85	45	130	-13%
Non malignant disorders	277	531	38	569	105%	2360	2624	1756	4380	86%
Bone Marrow Failures	154	234	8	242	57%	1292	1316	766	2082	61%
Hemoglobinopathies	72	213	3	216	200%	392	805	228	1033	164%
Immune deficiencies	41	74	16	90	120%	445	381	470	851	91%
Inherited diseases of metabolism	10	10	11	21	110%	177	63	154	217	23%
Autoimmune disorders	0	0	0	0	0	16	18	22	40	150%
Other Non malignant disorders	0	0	0	0	0	38	41	116	157	313%
Others	5	3	2	5	0	212	61	83	144	-32%
Total	803	1257	97	1354 (58,0%)	69%	20333	16305	17267	33572	65%
							48.6%	51.4%	47.3%
Autologous HSCT
Leukemias	58	n.a.	n.a.	34	-41%	1726	n.a.	n.a.	910	-47%
Lymphoproliferative disorders	338	n.a.	n.a.	840	148%	21655	n.a.	n.a.	33447	65%
Plasma cell disorders	127	n.a.	n.a.	404	218%	10675	n.a.	n.a.	18766	76%
Lymphomas	211	n.a.	n.a.	436	107%	10980	n.a.	n.a.	14681	34%
Solid tumors	29	n.a.	n.a.	101	248%	2560	n.a.	n.a.	2779	9%
Non malignant disorders	2	n.a.	n.a.	2	0	193	n.a.	n.a.	290	50%
Others	0	n.a.	n.a.	0		96	n.a.	n.a.	38	-60%
Total	427	n.a.	n.a.	977 (41,9%)	129%	26230	n.a.	n.a.	37464	43%
									52.7%
Total all HSCT	1230	n.a.	n.a.	2331	90%	46563	n.a.	n.a.	71036	53%

n.a.; not applicable